Growing evidence suggests that targeting cathepsins could be a therapeutic strategy to reduce NET-driven pathology in conditions such as cancer metastasis, autoimmune vasculitis, and ischemia–reperfusion injury. This evidence concerns the gene CTSS and autoimmune vasculitis.